Evidence map›Paper›PMID 39517096›Full record

ArticleThe FEBS journal2024

Structure of human phospholipase D3, a single-strand exonuclease associated with Alzheimer's disease.

Aleksandar Bijelic, Peter Macheroux

Abstract read
In one paragraph

Article in The FEBS journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Aleksandar BijelicInstitute of Biochemistry, Graz University of Technology, Austria.ORCID 0000-0002-8781-153X
Peter MacherouxInstitute of Biochemistry, Graz University of Technology, Austria.ORCID 0000-0002-0242-454X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Phospholipase D3 (PLD3) has emerged as an important 5'-exonuclease in charge of removing single-stranded DNA in lysosomes. Rare genetic variants of the gene encoding PLD3 have been implicated in late-onset Alzheimer's disease (AD). Ishii et al. have produced the soluble domain of human PLD3 with the aim of determining its three-dimensional structure using X-ray crystallography. The high-resolution structure (2.3 Å) provides new insights into the biochemical properties of the enzyme and paves the way to a deeper understanding of amino acid replacements affecting the stability and activity of the enzyme.

Indexed as

Alzheimer DiseasePhospholipase DCrystallography, X-RayExodeoxyribonucleasesHumansModels, MolecularExodeoxyribonucleasesPhospholipase DPLD3 protein, human5′‐exonucleaseAlzheimer's diseaseAβ‐homeostasishuman phospholipase D3

Identifiers

PMID39517096
PMCPMC11653683

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.